Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) had its price objective lowered by HC Wainwright from $14.00 to $11.00 ...

H.C. Wainwright lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $11 from $14 and keeps a Buy rating on the shares. Johnson ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 13,196 call options on the stock. This represents an increase of ...

Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals (NASDAQ:RVPH). And retail traders should know. We noticed this today when the trades showed up on ...

Reviva Pharmaceuticals Holdings Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 90.48%. The profit margin, also known as the revenue ratio or gross ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage ...

EF Hutton has initiated coverage on Reviva Pharmaceuticals (NASDAQ: RVPH), issuing a Buy rating with a price target of $15.00. The firm's optimism is primarily driven by the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.